This year's Alzheimer's Association International Conference drew 4,000 attendees to Washington, D.C., where they soaked up everything from advances in human imaging and diagnostics to the latest clinical trial results. While the latter brought no surprises, scientists shared plenty of interesting preclinical data as well, among them a massive combination trial of two anti-Aβ therapies and research that shows that aerobic exercise preserves cognitive function even in people who are already impaired.
Dose permutations point to synergistic effects on Aβ and amyloid plaques.
Probing this this Alzheimer’s risk factor, scientists find a novel variant, but no consensus yet on how this cell surface receptor increases risk for disease.
Tiny injuries to capillaries in white matter, and to cells in gray matter, have come to be the focus of new imaging measures being explored in early presymptomatic AD.
At AAIC, new data on three anti-Aβ antibodies reinforced a sense of hope that Aβ immunotherapy may yet work out. Challenges with each antibody notwithstanding, all four leading candidates, including crenezumab, are now in Phase 3.
At the right intensity and treatment duration, aerobic exercise can sharpen thinking skills and improve brain function even in cognitively impaired people, say researchers.
Researchers report multiple benefits of aerobic exercise on brain function, including some hints it could slow tau pathology.
Scientists are coming to grips with how tau spreads, and what the consequences are for the brain.
Variability still plagues CSF biomarker measurements, but automated systems offer hope of a diagnostic assay.
Research uncovers subtle links between early development problems and some forms of dementia.
The synaptic protein abounds in the cerebrospinal fluid of AD patients and in those in the prodromal phase of the disease.
Prevention trials are testing new protocols for telling potential participants about their heightened risk for dementia, and exploring the psychological effect of such disclosures.
The largest trial yet of ApoE4 carriers is pioneering new protocols with increasing use of technology to reach thousands of potential participants and disclose risk information.
Scanning for amyloid plaques in the brain may help clinicians diagnose and manage patients with a questionable diagnosis of Alzheimer’s.
At AAIC, researchers reported that estrogen may decrease dementia risk if given to healthy women during early menopause.
Scientists struggle to understand neurodegeneration in the SNAP syndrome.